Skip to content
Clinical Trials – home
SwedenBack to Sweden

Clinical trials in Sandviken

41 clinical trials in Sandviken, Sweden. Every trial is listed in the EU Clinical Trials Register and updated daily.

SwedenOur site in SwedenKliniska-Provningar.se(opens in a new tab)
Sandviken at a glance
41
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

41 trials in Sandviken

Open in trial search

Study on the Safety and Effectiveness of EIK1001 and Pembrolizumab for Patients with Advanced Melanoma

Registered drug
Countries:SwedenSweden
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Eikon Therapeutics Inc.

Colorectal cancer+2

Recruiting

Study of RMC-6291 with ivonescimab drug combination in patients with advanced RAS‑mutated solid tumors

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Revolution Medicines Inc.

Pumitamig Versus Durvalumab in Patients With Unresectable Stage III Non-Small Cell Lung Cancer Without Progression After Chemoradiation

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Pumitamig Versus Pembrolizumab in Patients With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

A Study of BI 764532, Atezolizumab, Carboplatin, and Etoposide in Patients With Extensive-Stage Small Cell Lung Cancer

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Boehringer Ingelheim Espana S.A.

Comparing sotorasib and pembrolizumab with chemotherapy for patients with advanced non-small cell lung cancer and a KRAS G12C mutation

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:Amgen Inc.

A Study Comparing PF-08046054 to Docetaxel in Adults with Previously Treated PD-L1 Positive Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Docetaxel
  • Sponsor:Pfizer Inc.

Study of rituximab followed by cladribine for patients with relapsing-remitting multiple sclerosis with less than 10 years disease duration

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years
  • Substances:Aciclovir sodium
  • Sponsor:Region Uppsala
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Ciprofloxacin
  • Sponsor:Region Uppsala

Study on HPV Vaccine and Screening to Reduce HPV Infection and Cervical Cancer in Swedish Women Aged 23-25

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · Healthy volunteers
  • Substances:Human Papillomavirus Type 11 L1 Protein - Adsorbed - In The Form Of Virus-Like Particles Produced In Yeast Cells (Saccharomyces Cerevisiae Canade 3C-5 (Strain 1895)) By Rdna
  • Sponsor:Region Stockholm

Study Comparing Chemotherapy Options for Patients with Stage I Testicular Cancer: Bleomycin, Etoposide, Cisplatin vs. Carboplatin

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years
  • Substances:Bleomycin
  • Sponsor:St. Olavs Hospital HF

Study on EGFR-Mutated Lung Cancer: Evaluating Dacomitinib, Afatinib, and Osimertinib for Patients Not Suitable for Curative Treatment

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Afatinib
  • Sponsor:Region Skane

Other cities in Sweden

The busiest research cities in the country

All 66 cities in Sweden
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.